🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Early-stage trial launches dropped 35% after the IRA. The orange line shows the decline in activity, diverging from the pre-IRA trend. Our study connects this shift to reduced investment in small molecule innovation: buff.ly/lkhuOjP We Work For Health #IRA #PillPenalty

We spoke with steve usdin about the effects of IRA’s 9-year vs 13-year protection. Our research shows it channels early-stage funding to biologics over pills. Lower costs undermine future development Listen to the full conversation: buff.ly/9ZuZR3K We Work For Health

The IRA’s 9-year cap for small molecules and 13-year cap for biologics rerouted investment away from the pills seniors rely on. We sat down with steve usdin to unpack how this shift skews R&D incentives and future therapies. Listen here: buff.ly/9ZuZR3K We Work For Health

Richard Z. Xie, Tess Cameron & Peter Kolchinsky show the IRA’s nine-year window wipes out small-molecule profits after Year 9, slashing NPV ~40%. Our analysis confirms this pill penalty deters critical small-molecule investment. Read: buff.ly/nKViEnO No Patient Left Behind

President Trump’s new order moves to end the IRA’s “pill penalty.” Our research shows median investment in key small-molecule therapies fell from $175M to $45M. The policy aims to bring that investment back: buff.ly/5oFWhrA #IRA #DrugPricing #PillPenalty We Work For Health

Medicare’s nine-year price cap erodes ~40% of a small-molecule project’s value before trials, sidelining therapies for aging - extending it to 13 years would restore innovators’ financial runway. Read more: buff.ly/4w5EV5P We Work For Health No Patient Left Behind #Pharma #PillPenalty

Early-stage small-molecule funding plunged 68% overall and 74% for high-Medicare-exposure programs, even as large-molecule investments rose ten times. Investors are shifting toward biologics under the IRA’s two-tier pricing. Read: buff.ly/CrTmhOr We Work For Health

Small‑molecule drugs face Medicare negotiations four years earlier than biologics, slashing early‑stage funding by nearly 70%. Affordable pills are disappearing, and vital therapies are at risk. Read the PhRMA article: buff.ly/1mGUHHS We Work For Health

We sat down with steve usdin to unpack how tariffs, the IRA, NIH/FDA budget cuts, science skepticism, and China’s surge in clinical filings are shaping U.S. life sciences. Listen to the full conversation here: buff.ly/hTEkOlm BioCentury We Work For Health

Science communication matters: the IRA, sold as cost‑savers, cut small‑molecule R&D and hurt patient access. Duane Schulthess, Joseph Hammang, and Harry Bowen talk with MSD Europe's Virginia Acha about the IRA’s pill penalty and tariffs. Listen: buff.ly/Ak471OS

On the latest Vital Health Podcast, we explore how the IRA’s shortened market exclusivity for small‑molecule drugs drags down innovation and availability - and why lost R&D momentum takes decades to rebuild. 🎧 Listen: buff.ly/2pntT5M We Work For Health MSD Europe

Our latest Vital Health Podcast unpacks why tying U.S. drug prices to lower-cost international markets - a policy known as reference pricing - can backfire, undermining patient access. In this episode, Duane Schulthess sits with Joseph Hammang, Ph.D., Harry Bowen and

Policy decisions set the stage for every step of drug development: they determine how long a treatment can be exclusive, when prices come under negotiation, and which discoveries qualify for special incentives. These rules guide manufacturers as they decide where to invest

CMS’s Medicare price controls under the IRA aren’t lowering patient out‑of‑pocket costs or delivering promised savings. It’s driven small‑molecule R&D down 70% and jeopardized thousands of American jobs: buff.ly/PacCArl Dan Leonard @WeWorkForHealth #IRA

The human brain is protected by a fortress: the blood-brain barrier. It is a layer of cells lining blood vessels in our brain that blocks most large molecules from ever reaching their target, so even the most promising therapies cannot get in to do their work. For

Rob Davis, Merck CEO, warns the IRA’s push to cut out‑of‑pocket costs is undercutting small‑molecule R&D. Policy must balance affordability with sustaining future breakthroughs. buff.ly/cDV4LRw PhRMA @WeWorkForHealth

Access to a medical breakthrough at exactly the right moment can mean the difference between years of uncertainty and a future full of possibility. After surviving a transplant, Donna Cryer saw firsthand how timely innovation saved her life and opened doors to a career, a

Imagine you’re someone looking to invest in an apartment complex. One property is in a city that caps rents after nine years, the other in a suburb that lets you raise rents freely until year thirteen. That extra four-year window can mean millions more in income, which is exactly

Planning a new medicine while the finance ministry, research universities, and hospitals never talk to each other leads to wasted effort. Sweden addressed this by creating an Office for Life Sciences inside the government that unites health, treasury, education, and industry

Sweden’s national life sciences strategy is built around a clear goal - tackling society’s biggest health challenges head-on. It brings together universities, hospitals, regulators, and industry under a single governance structure so that research, education, innovation, pharma,